BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday,
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative
Industry veteran brings extensive experience leading high-performing R&D groups BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 11, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its innovative
Strong Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018 MONOVISC and CINGAL Global Revenue Increased 14% for Full Year of 2018 BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2018 financial results after the close of the market on Thursday, February 21, 2019 and hold its investor conference call on the
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 16, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase HYALOFAST , a
BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 12, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its entire
Company Expands HYALOFAST Commercial Reach in Asia , the Middle East and Latin America BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 4, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
